AstraZeneca results: H1 and Q2 2026

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Total Revenue for FY 2026 is expected to increase by a mid-to-high single-digit percentage at CER.

  60% confidence

• AstraZeneca saw strong H1 2026 performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets, including US approval of Baxfendy for hypertension.

  60% confidence

• Core EPS for FY 2026 is expected to increase by a low double-digit percentage at CER.

  60% confidence

• The Core Tax rate is expected to be between 18-22% for FY 2026.

  60% confidence

• AstraZeneca continues to invest in transformative technologies and commercial execution to drive growth beyond 2030.

  60% confidence

• If FX rates from July-December 2026 remain at June 2026 average levels, FY2026 Total Revenue would see a low single-digit percentage positive benefit versus CER performance, and Core EPS growth would be broadly similar to CER growth.

  60% confidence

• Despite disappointment over the CARDIO-TTRansform trial outcome, AstraZeneca remains on track for its $80bn Total Revenue ambition and is confident in its pipeline, with more than twenty high-value readouts due over the next 18 months.

  60% confidence

Data points we hold from this source